“Nearly 20 million measles-related deaths have been averted in Africa since 2000 thanks to increasing vaccination coverage, according to the first-ever detailed analysis of immunization targets on the continent. 

The analysis, by World Health Organization (WHO) in the African region, and Gavi, the Vaccine Alliance, also found that alongside the 19.5 million measles deaths averted, more than 500 million children in Africa have been protected through routine immunization between 2000 and 2024.”

From World Health Organization.

“The proportion of [donation after circulatory death donors (DCD)] in the US increased from 2% in 2000 to 49% in 2025, a period in which the number of DCD donors increased from 118 in 2000 to 8129 in 2025, while donation after [brain death donors (DBD)] rose from 5,849 to 8416…

DCD donors now comprise about half of DD, including most donors at 44% of OPOs. Further, contemporary DCD donors are more medically complex than those from prior eras. This growing reliance on DCD organs to maintain transplant access necessitates establishing best practices in DCD organ selection, preservation, and allocation. Recent innovations have facilitated recovery from medically complex DCD donors. Normothermic regional perfusion, in which perfusion is restored in situ to limited organs after circulatory death, contributed to the rise in recovery of DCD organs since its use began increasing in 2019. The regulatory approval of normothermic machine perfusion for livers (2021) contributed to the subsequent acceleration of DCD liver recovery, and normothermic machine perfusion enabled the advent of DCD heart transplantation in 2019.”

From JAMA.

“Eli Lilly and Company (NYSE: LLY) today announced positive topline results from the Phase 3 ACHIEVE-4 trial evaluating the efficacy and safety of Foundayo (orforglipron), compared to insulin glargine in adults with type 2 diabetes and obesity or overweight at increased cardiovascular risk. ACHIEVE-4, the largest and longest study of Foundayo in type 2 diabetes to date, enrolled more than 2,700 participants across 15 countries. In the trial, Foundayo met the primary endpoint by demonstrating a non-inferior risk of major adverse cardiovascular events (MACE-4), including cardiovascular death, heart attack, stroke or hospitalization for unstable and sudden chest pain, compared to insulin glargine. In addition, Foundayo showed superior improvements in A1C and body weight at 52 weeks vs. insulin glargine, which persisted through 104 weeks of therapy. While not controlled for multiplicity, the risk of all-cause death was significantly lower for Foundayo vs. insulin glargine.”

From Eli Lilly and Company.

“A new pill called baxdrostat is showing strong results in lowering dangerously high blood pressure in people who don’t respond to standard treatments. In a large global trial, patients saw their blood pressure drop by nearly 10 mmHg, a meaningful reduction that can significantly lower the risk of heart attack, stroke, and kidney disease. By targeting a hormone that causes the body to retain salt and water, this treatment could offer a much-needed solution for millions struggling with uncontrolled hypertension.”

From ScienceDaily.